Driving their expertise in genomics-based health and disease testing, Genetic Technologies (ASX: GTG) has partnered CancerIQ, a widely used platform that assists healthcare providers identify high-risk patients and prioritise preventive cancer screenings.
CancerIQ has become a resource for healthcare institutions and clinics by simplifying the identification of individuals at risk for hereditary cancers. By embedding genetic testing tools directly into clinic operations, particularly in breast imaging centres, CancerIQ has increased the uptake of genetic testing and the identification of at-risk patients for preventive care. Previously, their offerings were limited to traditional risk assessment models and germline testing for hereditary cancer risk.
With the integration of Genetic Technologies’ geneType tests, CancerIQ will now expand its focus beyond hereditary risk to include polygenic-integrated clinical risk prediction across a range of diseases. This addition aligns with Genetic Technologies’ mission of advancing population-wide healthcare, offering risk assessments for nine major diseases, including cancer and cardiometabolic conditions.
Genetic Technologies, through its geneType and EasyDNA brands, provides genomics-based tests for health and serious disease. Their proprietary risk stratification platform combines genetic and clinical data to deliver actionable insights for healthcare providers.
As part of its broader mission, Genetic Technologies is committed to improving healthcare outcomes by offering accessible, reliable risk assessments that empower both patients and practitioners to make informed decisions. The partnership with CancerIQ strengthens this objective by embedding their tests within a platform used by over 45 healthcare systems and 250 clinics in the United States, with a reach that has already seen more than one million patients screened.
This collaboration is expected to enhance Genetic Technologies’ visibility and accessibility within the US healthcare market.
This strategic move follows a period of limited commercial reach for Genetic Technologies in the US, where sales efforts had primarily focused on boutique clinics and large entities.
To further streamline the process for healthcare providers, CancerIQ will integrate geneType tests into its platform to simplify the workflow for both practitioners and patients, making genetic testing more accessible and efficient.
“We are very excited to have been invited to become part of the CancerIQ platform to be implemented upon completing our current capital raise,” said Genetic Technologies Chairman, Peter Rubinstein.
“This approach will make the geneType Risk Assessment Tests more easily accessible to the clinical community. We look forward to the co-marketing opportunities with CancerIQ to increase the awareness of population risk-assessment. We are confident in the value of this population healthcare approach, ultimately providing the opportunity to improve the health outcomes for people generally.”
As part of the agreement, Genetic Technologies will pay an annual fee of US$75,000 to access CancerIQ’s premium tier, providing the company with access to CancerIQ’s extensive network and tools to simplify the testing process.
Following news of the CancerIQ partnership, Genetic Technologies confirmed the results of its current capital raising campaign from shareholders, with the Entitlement Offer raising $324k.
These funds were supported by pre-commitments, shortfall commitments that took to total raise to $1 million, however at this stage all funds will be refunded if Genetic Technologies cannot raise the minimum amount required of $2 million as outlined in its Prospectus. The Company is now actively working with Brokers to place the shortfall.
Emily Maxwell is a business writer at The Sentiment with interest in the tech, fintech and retail industries.
Latest posts by Emily Maxwell (see all)
- PainChek locks in performance data for FDA submission, aiming to befirst pain assessment app approved in US - October 3, 2024
- HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use - September 30, 2024
- ClearVue ventures into net-zero modular housing market with Prefabulous - September 27, 2024
Leave a Comment
You must be logged in to post a comment.